[No abstract available]373211214Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders (2005) Lancet, 365 (9464), pp. 1054-1061Thoennissen, N.H., Krug, U.O., Lee, D.H., Kawamata, N., Iwanski, G.B., Lasho, T., Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms (2010) Blood, 115 (14), pp. 2882-2890Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C., Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 (2013) N Engl J Med, 369 (25), pp. 2391-2405Klampfl, T., Gisslinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milosevic, J.D., Somatic mutations of calreticulin in myeloproliferative neoplasms (2013) N Engl J Med, 369 (25), pp. 2379-2390Tefferi, A., Lasho, T.L., Finke, C.M., Knudson, R.A., Ketterling, R., Hanson, C.H., CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons (2014) Leukemia, 28 (7), pp. 1472-1477Rotunno, G., Mannarelli, C., Guglielmelli, P., Pacilli, A., Pancrazzi, A., Pieri, L., Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia (2014) Blood, 123 (10), pp. 1552-1555Wu, Z., Zhang, X., Xu, X., Chen, Y., Hu, T., Kang, Z., The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms (2014) J Hematol Oncol, 7, p. 48Shen, H., Chao, H., Ding, Z., Feng, Y., Cen, J., Pan, J., CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia (2014) Leuk Lymphoma, pp. 1-9Li, B., Xu, J., Wang, J., Gale, R.P., Xu, Z., Cui, Y., Calreticulin mutations in Chinese with primary myelofibrosis (2014) Haematologica, 99 (11), pp. 1697-1700McGaffin, G., Harper, K., Stirling, D., McLintock, L., JAK2 V617 F and CALR mutations are not mutually exclusivefindings from retrospective analysis of a small patient cohort (2014) Br J Haematol, 167 (2), pp. 276-278Rampal, R., Al-Shahrour, F., Abdel-Wahab, O., Patel, J.P., Brunel, J.P., Mermel, C.H., Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis (2014) Blood, 123 (22), pp. e123-e133da Silva, R.R., Domingues Hatzlhofer, B.L., Machado, C.G., Lima, A.S., de Albuquerque, D.M., dos Santos, M.N., JAK2 V617 F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil (2012) Genet Test Mol Biomarkers, 16 (7), pp. 802-805Chi, J., Nicolaou, K.A., Nicolaidou, V., Koumas, L., Mitsidou, A., Pierides, C., Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis (2014) Leukemia, 28 (5), pp. 1152-1154Chen, C.C., Gau, J.P., Chou, H.J., You, J.Y., Huang, C.E., Chen, Y.Y., Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia (2014) Ann Hematol, 93 (12), pp. 2029-2036